A novel implantable sensor for long-term continuous glucose - - PowerPoint PPT Presentation

▶
a novel implantable sensor for long term continuous
SMART_READER_LITE
LIVE PREVIEW

A novel implantable sensor for long-term continuous glucose - - PowerPoint PPT Presentation

Feb 04, 2023 167 likes •403 views

A novel implantable sensor for long-term continuous glucose measurement Investor Presentation at November 29th - 2019 1 Lifecare AS is developing an implantable glucose sensor named SENCELL for positioning under the skin into the

slide-1
SLIDE 1

1

A novel implantable sensor for long-term continuous glucose measurement

Investor Presentation at

November 29th - 2019

slide-2
SLIDE 2

2

Lifecare AS is developing an implantable glucose sensor named SENCELL for positioning under the skin into the interstitial space.

slide-3
SLIDE 3

3

slide-4
SLIDE 4

4

slide-5
SLIDE 5

5

BGM versus CGM

slide-6
SLIDE 6

6

$ 5 CGM - sales in M$ Others Abbott Dexcom Medtronic $ 909 $ 594 $ 300 $ 1.415 $ 200 $ 899 $ 477 $ 221 2017 2018

  • 1. H 2019

$ 68 $ 815 $ 418

slide-7
SLIDE 7

7

$ 502 Others Abbott Dexcom Medtronic $ 702 $ 111 $ 81 $ 853 $ 1.175 $ 192 $ 112 $ 539 $ 740 $ 125 $ 70 2017 2018

  • 1. H 2019

CGM - sales in M$

slide-8
SLIDE 8

8

$ 76 RoW Europe U.S. $ 1.687 $ 702 $ 909 $ 2.728 $ 113 $ 1.753 $ 740 $ 899 2017 2018

  • 1. H 2019

$ 137 $ 1.175 $ 1.415 WW CGM - sales in M$

slide-9
SLIDE 9

9

According to Harold Schnitzer Diabetes Health Center US presented at Diabetes Technology Meeting US 2017”, this is what the diabetes patient wants for a CGM (continuous glucose measurement) device; # 1) Simple & Affordable # 2) Covered by insurance # 3) Long wear time # 4) High usability with integration # 5) Excellent accuracy # 6) No calibration required # 7) No interference # 8) No compression artifact # 9) Inconspicuous (not readily visible to others) # 10) Safe & comfortable # 11) Accessible data

slide-10
SLIDE 10

Competitive L Landscape

10

slide-11
SLIDE 11

➢ No reagent consump mption ➢ High glucose e specifi ficity ➢ Long term m stability ➢ Univer ersal calibra ration ➢ No intern rnal power r supply ➢ No genera ration of poisonous by-products ➢ No additional start-up time ➢ Miniaturi riza zation ➢ Unobtru rusive ➢ Implantation by injec ections/mi minima mal surgery ➢ Real time e continuous operation ➢ Wirel eless commu munication

Low w cost t operatio ration

Osmoti tic c pressu ssure measu sureme ment nt offe fers s seve veral major advanta ntages

slide-12
SLIDE 12

12

  • 1. Digitaliza

zation

  • 2. Urban

n Mobility

  • 3. Machine

hine Learni ning

  • 4. Demography
  • 5. Green

n World

Internet et of

  • f things

E-commerce Industri rial LoT Infrastru ructure Self driving cars El cars Robotics Artifi ficial Intelligens Big Data & Clouding Generation X Healthy Lifes festyle Aging (Bio-T ec ech) Renewa wable Energy Circular (and Water) er) Electri rifying

Commun unication Trans nsportation Offi fice and Home Health h (care) Energy

slide-13
SLIDE 13

13

  • Increas

ase market ket shar are

Help people with diabetes live full, healthy lives by developing comprehensive solutions that combine devices, software, medicine, and professional care to enable simple and intelligent disease management

  • AI
  • Big Data
  • Robotics
  • CGM

CGM: disruptive diabetes innovation today and near future

Meeting ng the needs ➢ Long-T erm m use ➢ No body worn devices ➢ Convenie ient ➢ Lower cost of

  • f care

➢ Actionab nable data ➢ Higher sens nsivi vity ➢ Improve ved quality of

  • f life

fe

slide-14
SLIDE 14

14 Double membrane patent 2004

  • Composition of membranes
  • A pressure sensor with a chamber on each side, where the two chambers have

individual semi-permeable membranes

  • Applies in USA, Canada, India, China, Japan, Norway, EPO(1)

Augmented osmotic pressure patent 2009

  • Apparatus for measuring augmented osmotic pressure
  • Patent applies in US
  • Approved EPO

Chemistry

  • Active fluid composition and method of production and method of production of active

fluid, which can be used in a sensor for measurement of glucose concentrations in fluids

  • Pending (Norway)

Dual sensor patent

  • Implantable sensor with two chambers, each with a pressure sensor
  • Pending
slide-15
SLIDE 15

15

Meeting the needs ➢ Long-Term use ➢ No body worn devices ➢ Convenient ➢ Lower cost of care ➢ Actionable data ➢ Higher sensivity ➢ Improved quality of life

Date: 25/11/2019 Number of investors: 311 Number of shares: 80 925 000 Holding Stake Name 15 032 030 18,57526 BECH INVEST AS 14 809 477 18,30025 TEIGLAND EIENDOM AS 10 658 301 13,17059 LACAL AS 7 634 920 9,42345 VERDIPAPIRFONDET NORDEA AVKASTNING 6 054 936 7,48216 SPAREBANKEN VEST 3 900 000 4,81928 STERNA HOLDING AS 3 787 879 4,68073 MP PENSJON PK 3 781 104 4,67236 Danske Invest Norge Vekst 1 812 500 2,23973 Deutsche Bank Aktiengesellschaft 1 587 358 1,96152 Rieber & Søn AS 1 515 152 1,87229 NORDA ASA 1 331 355 1,64517 CIMTER AS 710 012 0,87737 PROBE AS 689 379 0,85187 NEXUS MARKETING 590 625 0,72984 CLEARSTREAM BANKING S.A. 6 424 944 7,93938 Other 80 925 000 100

slide-16
SLIDE 16

R&D Progress

16

slide-17
SLIDE 17

17

Semi-permeable membrane Active fluid Encapsulant Electronic sensor Carrier Glucose molecule Transfer of data Power supply

1 Glucose molecules pass through the semi-permeable membrane and into the micro-sensor

1

High concentrations of glucose induce ConA and Dextran dissociation and the formation of two new molecules: ConA / glucose and Dextran

2b

The active fluid contains two molecules, Concanavalin A (ConA) and Dextran, which will bind together in the absence of glucose

2a

The increase in osmotic pressure, equivalent to the number of bound glucose molecules, is measured as the difference in pressure between the active and reference fluid

3

Pressure signals are conveyed to the electronic sensor and sent to an external reader

5

The pressure sensor detects the increase in the osmotic pressure

4

5

Illus ustration n of step 2

a b Con A Dextran Glucose

Pressure sensor Pressure sensor Reference fluid Semi-permeable membrane

2 3 4 4

slide-18
SLIDE 18

Overview – Development Strategy

Macro Cell ll Senc ncell ll Miniatur turiz ized Senso nsor

Starting from a laboratory working cell (5 x 3 x 3 cm), the company has achieved significant miniaturization and has performed preclinical proof-

  • f-concept with a small working

sensor model (2 x 1 x 0.5 cm)

slide-19
SLIDE 19

19

Pre -clinical

  • Each system consists of four similar hand made sensor implants wired to a break-out box that collected

measurement data for the duration of the trial, and 1-2 Dexcom4 devices.

  • The sensors were designed against requirements (size, materials, etc.) agreed with Sciema and MfD to

make them suitable for implantation

  • Sensors were tested in Cambridge prior to shipping to Germany
  • No sensor tests were undertaken on site prior to implantation

Dexcom 4 Dexcom 6

slide-20
SLIDE 20

Calibration Protocol

  • Measure Sensor Signal at -00 mbar pressure
  • Measure Sensor Signal at -20 mbar pressure
  • Measure Sensor Signal at -35 mbar pressure
  • Measure Sensor Signal at -20 mbar pressure
  • Measure Sensor Signal at -00 mbar pressure
  • Measure Sensor Signal at -20 mbar pressure
  • Etc….

R / kΩ 0 mbar 20 mbar 35 mbar 20 mbar 0 mbar

  • 20 mbar
  • 35 mbar

Measurement Curve

This prot

  • tocol
  • col yield

lds

  • Calibration Curve
  • Signal Hysteresis

(Stability)

  • Signal Stability

(Resolution)

Experimental Analysis – Nanosensor Performance

slide-21
SLIDE 21

21

Overview - Optimized D Development Strategy

Preclinical I Preclinical II Laboratory Cell

Sencell

Needle Mounted Sencell

slide-22
SLIDE 22

22

R&D P Progress

  • Layout o
  • f N

Needle S Sensor

Sensor Cutout

Needle Type Sensor

  • Wired Interface
  • Easy Signal Read-Out
  • Sensor in Needle
  • Protected
  • Measuring Conditions
  • Fully Controlled
slide-23
SLIDE 23

24 24

Let’s Execute cute for Improv

  • ved

ed Value ue Creation ation

Sencell ell - Driven en by by Natur ture